Elitek (Sanofi-Synthelabo Inc)
Elitek (Sanofi-Synthelabo Inc) Brand names, Elitek (Sanofi-Synthelabo Inc) Analogs
Elitek (Sanofi-Synthelabo Inc) Brand Names Mixture
- No information avaliable
Elitek (Sanofi-Synthelabo Inc) Chemical_Formula
C1521H2381N417O461S7
Elitek (Sanofi-Synthelabo Inc) RX_link
http://www.rxlist.com/cgi/generic3/elitek.htm
Elitek (Sanofi-Synthelabo Inc) fda sheet
Elitek (Sanofi-Synthelabo Inc) msds (material safety sheet)
Elitek (Sanofi-Synthelabo Inc) Synthesis Reference
No information avaliable
Elitek (Sanofi-Synthelabo Inc) Molecular Weight
34109.5
Elitek (Sanofi-Synthelabo Inc) Melting Point
No information avaliable
Elitek (Sanofi-Synthelabo Inc) H2O Solubility
No information avaliable
Elitek (Sanofi-Synthelabo Inc) State
Liquid
Elitek (Sanofi-Synthelabo Inc) LogP
-0.465
Elitek (Sanofi-Synthelabo Inc) Dosage Forms
Powder for solution
Elitek (Sanofi-Synthelabo Inc) Indication
For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)
Elitek (Sanofi-Synthelabo Inc) Pharmacology
Drugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.
Elitek (Sanofi-Synthelabo Inc) Absorption
No information avaliable
Elitek (Sanofi-Synthelabo Inc) side effects and Toxicity
No information avaliable
Elitek (Sanofi-Synthelabo Inc) Patient Information
No information avaliable
Elitek (Sanofi-Synthelabo Inc) Organisms Affected
Humans and other mammals
